Dublin, April 08, 2019 (GLOBE NEWSWIRE) -- The "Cough - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Cough - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Cough (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cough (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cough and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 2, 11, 4, 9 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Cough (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Cough (Respiratory).
• The pipeline guide reviews pipeline therapeutics for Cough (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Cough (Respiratory) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Cough (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Cough (Respiratory)

Key Topics Covered:

1. Introduction
2. Cough - Overview
3. Cough - Therapeutics Development
4. Cough - Therapeutics Assessment
5. Cough - Companies Involved in Therapeutics Development
6. Cough - Drug Profiles
7. Cough - Dormant Projects
8. Cough - Discontinued Products
9. Cough - Product Development Milestones
10. Appendix

Companies Mentioned

• Alitair Pharmaceuticals Inc
• Bayer AG
• Beijing Tide Pharmaceutical Co Ltd
• Charleston Laboratories Inc
• Conrig Pharma ApS
• Develco Pharma Schweiz AG
• Evotec AG
• Grunenthal GmbH
• Hyundai Pharmaceutical Co Ltd
• Merck & Co Inc
• Orbis Biosciences Inc
• PhytoHealth Corp
• Roivant Sciences Ltd
• Shionogi & Co Ltd
• SolAeroMed Inc
• Tris Pharma Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/w56sxk

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Over the Counter (OTC) Drugs

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.